<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04456348</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1312900-01</org_study_id>
    <nct_id>NCT04456348</nct_id>
  </id_info>
  <brief_title>Association Between Gait Assessed by Intelligent System and Cognitive Function in Silent Cerebrovascular Disease</brief_title>
  <acronym>ACCURATE-2</acronym>
  <official_title>Association Between Gait Features Assessed by Artificial Intelligent System and Cognitive Function Decline in the Patients of Silent Cerebrovascular Disease: A Multicenter Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital Of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center prospective cohort study. We will continuously recruit subjects&#xD;
      with silent cerebrovascular disease aged 60 to 85 years from Shanghai and Guizhou. Data&#xD;
      including demographic characteristics, medical history, other concomitant diseases,&#xD;
      neurological function assessments, laboratory examinations, imaging examinations, and other&#xD;
      clinical data and health economics survey responses will be collected from all subjects.&#xD;
&#xD;
      At baseline, all subjects will undergo gait assessment using the intelligent system and&#xD;
      cognitive function scale assessment by clinicians. According to the intelligent gait results,&#xD;
      the subjects will be divided into normal and abnormal gait groups. All subjects will be&#xD;
      observed naturally for 1 year, and all medical behaviors will be recorded. All subjects will&#xD;
      be interviewed by telephone for the occurrence of vascular events and changes in medical&#xD;
      behaviors at half a year after enrollment and followed up at 1 year after enrollment,&#xD;
      including gait evaluation using the intelligent system and cognitive function scale&#xD;
      evaluation by clinicians. During the follow-up period, patients can visit the hospital for&#xD;
      follow-up at any time when their condition changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neurological function of all subjects was assessed based on the following tests under the&#xD;
      guidance of a physician. The timed up-and-go test was used to evaluate the subjects' gait&#xD;
      function, requiring them to stand up from their seat and walk straight forward for 3 meters,&#xD;
      turn around, walk straight back to the chair, and then sit down again. Using simple cognitive&#xD;
      evaluation (Mini-Cognitive Assessment) screening of the subjects' memory and executive&#xD;
      function, the participants will first be asked to remember three unrelated words and&#xD;
      immediately repeat the three words; they will then be asked to draw a clock marked with the&#xD;
      numbers and pointers, and eventually recall the three words. The verbal function of the&#xD;
      subjects will be assessed using the verbal retelling items in the MMSE and Montreal Cognitive&#xD;
      Assessment, asking the subjects to clearly repeat &quot;44 stone lions,&quot; &quot;I only know Zhang Liang&#xD;
      came to help today,&quot; and &quot;the cat always hid under the sofa when the dog was in the room.&quot;&#xD;
      Through the camera image data record, the intelligent system uses the built-in intelligent&#xD;
      algorithm for intelligent video gait recognition and neural networks based on depth&#xD;
      interpretation automation and automatic access to the subjects' gait characteristics&#xD;
      (stand-up time, turnaround time, stride length, step velocity, stride length, step width,&#xD;
      etc.), language features (pronunciation, intonation, word order, language accuracy, language&#xD;
      fluency, etc.), and clock features.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive assessment scale score(MMSE)</measure>
    <time_frame>1 year</time_frame>
    <description>It will be assessed by the Mini-Mental state examination (MMSE), which is scored 0-30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive assessment scale score(MoCA)</measure>
    <time_frame>1 year</time_frame>
    <description>It will be assessed by the Montreal cognitive assessment (MoCA), which is scored 0-30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prevalence of gait disorders</measure>
    <time_frame>baseline</time_frame>
    <description>the prevalence of gait disorders, according to the intelligent assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prevalence of cognitive disorder</measure>
    <time_frame>baseline</time_frame>
    <description>the prevalence of cognitive disorder, according to the MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of vascular events</measure>
    <time_frame>1 year</time_frame>
    <description>the incidence of vascular events, including Cardiovascular and cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of fall incidence</measure>
    <time_frame>1 year</time_frame>
    <description>the incidence of fall incidence</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Silent Stroke</condition>
  <arm_group>
    <arm_group_label>positive</arm_group_label>
    <description>Subjects have gait disorder according to intelligent gait assessment at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>negative</arm_group_label>
    <description>Subjects don't have gait disorder according to intelligent gait assessment at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>there is no intervention</intervention_name>
    <description>There is no intervention</description>
    <arm_group_label>negative</arm_group_label>
    <arm_group_label>positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        with silent cerebrovascular disease patient aged 60 to 85 in Shanghai and Guizhou&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 60 and 85 years.&#xD;
&#xD;
          2. Diagnosed with silent cerebrovascular disease/silent stroke, which is consistent with&#xD;
             the 2016 statement issued by the American Heart Association (AHA) and American Stroke&#xD;
             Association (ASA):&#xD;
&#xD;
               1. No previous clear history of stroke and no clinical symptoms or mild clinical&#xD;
                  symptoms that fail to attract clinical attention;&#xD;
&#xD;
               2. Cranial MRI showing at least one of the following within 5 years: lacunar infarct&#xD;
                  of vascular origin; white matter hyperintensity of vascular origin; cerebral&#xD;
                  microbleeds;&#xD;
&#xD;
          3. Consciousness and ability to complete cognitive assessment&#xD;
&#xD;
          4. Ability to stand and walk independently and complete gait assessment without&#xD;
             assistance from others.&#xD;
&#xD;
          5. Ability to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracranial lesions that have been clearly diagnosed as demyelination disease, white&#xD;
             matter dystrophy, intracranial space-occupying lesions, or autoimmune encephalitis.&#xD;
&#xD;
          2. Gait disorder that has been diagnosed as Parkinson's disease, normal cranial&#xD;
             hydrocephalus, an otogenic disease, subacute combined degeneration, peripheral&#xD;
             neuropathy, osteoarthritis, or lumbar disease.&#xD;
&#xD;
          3. Cognitive disorders that have been diagnosed, such as Alzheimer's disease,&#xD;
             frontotemporal dementia, Lewy body dementia, etc.&#xD;
&#xD;
          4. Severe neurological diseases such as previous cerebral trauma, epilepsy, and&#xD;
             myelopathy, etc.&#xD;
&#xD;
          5. Severe cardiovascular complications and intolerance to the assessment&#xD;
&#xD;
          6. Severe visual or hearing impairment, aphasia, cognitive disorder, gait disorder, etc.,&#xD;
             that results in the inability to cooperate for cognitive and gait assessment&#xD;
&#xD;
          7. Refusal to participate in the study&#xD;
&#xD;
          8. Other anomalies that could not be included in the exclusion criteria, but are&#xD;
             considered inappropriate to be included in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Ding, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beini Fei, MB</last_name>
    <phone>+86 13701699684</phone>
    <email>fbeini@sina.com</email>
  </overall_contact>
  <reference>
    <citation>Poels MM, Steyerberg EW, Wieberdink RG, Hofman A, Koudstaal PJ, Ikram MA, Breteler MM. Assessment of cerebral small vessel disease predicts individual stroke risk. J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1174-9. doi: 10.1136/jnnp-2012-302381. Epub 2012 Aug 23.</citation>
    <PMID>22917672</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Lee SH. Prognostic Impact of Cerebral Small Vessel Disease on Stroke Outcome. J Stroke. 2015 May;17(2):101-10. doi: 10.5853/jos.2015.17.2.101. Epub 2015 May 29.</citation>
    <PMID>26060797</PMID>
  </reference>
  <reference>
    <citation>Sachdev PS, Wen W, Christensen H, Jorm AF. White matter hyperintensities are related to physical disability and poor motor function. J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):362-7. doi: 10.1136/jnnp.2004.042945.</citation>
    <PMID>15716527</PMID>
  </reference>
  <reference>
    <citation>Murray ME, Senjem ML, Petersen RC, Hollman JH, Preboske GM, Weigand SD, Knopman DS, Ferman TJ, Dickson DW, Jack CR Jr. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol. 2010 Nov;67(11):1379-85. doi: 10.1001/archneurol.2010.280.</citation>
    <PMID>21060015</PMID>
  </reference>
  <reference>
    <citation>Wakefield DB, Moscufo N, Guttmann CR, Kuchel GA, Kaplan RF, Pearlson G, Wolfson L. White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults. J Am Geriatr Soc. 2010 Feb;58(2):275-81. doi: 10.1111/j.1532-5415.2009.02699.x. Epub 2010 Jan 26.</citation>
    <PMID>20374403</PMID>
  </reference>
  <reference>
    <citation>Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010 Jul 26;341:c3666. doi: 10.1136/bmj.c3666.</citation>
    <PMID>20660506</PMID>
  </reference>
  <reference>
    <citation>Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012 Dec;69(12):1621-7. doi: 10.1001/archneurol.2012.1527.</citation>
    <PMID>22945686</PMID>
  </reference>
  <reference>
    <citation>Maillard P, Carmichael O, Fletcher E, Reed B, Mungas D, DeCarli C. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology. 2012 Jul 31;79(5):442-8. doi: 10.1212/WNL.0b013e3182617136. Epub 2012 Jul 18.</citation>
    <PMID>22815562</PMID>
  </reference>
  <reference>
    <citation>Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Greenberg SM, Higashida RT, Kasner SE, Seshadri S; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Feb;48(2):e44-e71. doi: 10.1161/STR.0000000000000116. Epub 2016 Dec 15.</citation>
    <PMID>27980126</PMID>
  </reference>
  <reference>
    <citation>Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54. doi: 10.1016/s0140-6736(13)61953-4. Erratum In: Lancet. 2014 Jan 18;383(9913):218.</citation>
    <PMID>24449944</PMID>
  </reference>
  <reference>
    <citation>Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16(3):280-5. doi: 10.1159/000071128.</citation>
    <PMID>12865617</PMID>
  </reference>
  <reference>
    <citation>Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003 May;34(5):1126-9. doi: 10.1161/01.STR.0000068408.82115.D2. Epub 2003 Apr 10.</citation>
    <PMID>12690219</PMID>
  </reference>
  <reference>
    <citation>Kim YJ, Kwon HK, Lee JM, Cho H, Kim HJ, Park HK, Jung NY, San Lee J, Lee J, Jang YK, Kim ST, Lee KH, Choe YS, Kim YJ, Na DL, Seo SW. Gray and white matter changes linking cerebral small vessel disease to gait disturbances. Neurology. 2016 Mar 29;86(13):1199-207. doi: 10.1212/WNL.0000000000002516. Epub 2016 Mar 2.</citation>
    <PMID>26935893</PMID>
  </reference>
  <reference>
    <citation>de Laat KF, van Norden AG, Gons RA, van Oudheusden LJ, van Uden IW, Bloem BR, Zwiers MP, de Leeuw FE. Gait in elderly with cerebral small vessel disease. Stroke. 2010 Aug;41(8):1652-8. doi: 10.1161/STROKEAHA.110.583229. Epub 2010 Jun 24.</citation>
    <PMID>20576951</PMID>
  </reference>
  <reference>
    <citation>Montero-Odasso MM, Sarquis-Adamson Y, Speechley M, Borrie MJ, Hachinski VC, Wells J, Riccio PM, Schapira M, Sejdic E, Camicioli RM, Bartha R, McIlroy WE, Muir-Hunter S. Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment: Results From the Gait and Brain Study. JAMA Neurol. 2017 Jul 1;74(7):857-865. doi: 10.1001/jamaneurol.2017.0643. Erratum In: JAMA Neurol. 2017 Nov 1;74(11):1381.</citation>
    <PMID>28505243</PMID>
  </reference>
  <reference>
    <citation>Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 Aug;12(8):822-38. doi: 10.1016/S1474-4422(13)70124-8.</citation>
    <PMID>23867200</PMID>
  </reference>
  <results_reference>
    <citation>Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007 Jul;6(7):611-9. doi: 10.1016/S1474-4422(07)70170-9.</citation>
    <PMID>17582361</PMID>
  </results_reference>
  <results_reference>
    <citation>Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med. 2002 Nov 28;347(22):1761-8. doi: 10.1056/NEJMoa020441.</citation>
    <PMID>12456852</PMID>
  </results_reference>
  <results_reference>
    <citation>Dumurgier J, Artaud F, Touraine C, Rouaud O, Tavernier B, Dufouil C, Singh-Manoux A, Tzourio C, Elbaz A. Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. J Gerontol A Biol Sci Med Sci. 2017 May 1;72(5):655-661. doi: 10.1093/gerona/glw110.</citation>
    <PMID>27302701</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04456348
org study id: 2018YFC1312900-01
nct id: NCT04456348
lead sponsor: 
collaborator: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
This study is a multi-center prospective cohort study. We will continuously recruit subjects
      with silent cerebrovascular disease aged 60 to 85 years from Shanghai and Guizhou. Data
      including demographic characteristics, medical history, other concomitant diseases,
      neurological function assessments, laboratory examinations, imaging examinations, and other
      clinical data and health economics survey responses will be collected from all subjects.

      At baseline, all subjects will undergo gait assessment using the intelligent system and
      cognitive function scale assessment by clinicians. According to the intelligent gait results,
      the subjects will be divided into normal and abnormal gait groups. All subjects will be
      observed naturally for 1 year, and all medical behaviors will be recorded. All subjects will
      be interviewed by telephone for the occurrence of vascular events and changes in medical
      behaviors at half a year after enrollment and followed up at 1 year after enrollment,
      including gait evaluation using the intelligent system and cognitive function scale
      evaluation by clinicians. During the follow-up period, patients can visit the hospital for
      follow-up at any time when their condition changes.
The neurological function of all subjects was assessed based on the following tests under the
      guidance of a physician. The timed up-and-go test was used to evaluate the subjects' gait
      function, requiring them to stand up from their seat and walk straight forward for 3 meters,
      turn around, walk straight back to the chair, and then sit down again. Using simple cognitive
      evaluation (Mini-Cognitive Assessment) screening of the subjects' memory and executive
      function, the participants will first be asked to remember three unrelated words and
      immediately repeat the three words; they will then be asked to draw a clock marked with the
      numbers and pointers, and eventually recall the three words. The verbal function of the
      subjects will be assessed using the verbal retelling items in the MMSE and Montreal Cognitive
      Assessment, asking the subjects to clearly repeat "44 stone lions," "I only know Zhang Liang
      came to help today," and "the cat always hid under the sofa when the dog was in the room."
      Through the camera image data record, the intelligent system uses the built-in intelligent
      algorithm for intelligent video gait recognition and neural networks based on depth
      interpretation automation and automatic access to the subjects' gait characteristics
      (stand-up time, turnaround time, stride length, step velocity, stride length, step width,
      etc.), language features (pronunciation, intonation, word order, language accuracy, language
      fluency, etc.), and clock features.
observational model: Cohort
time perspective: Prospective
measure: Change in cognitive assessment scale score(MMSE)
time frame: 1 year
description: It will be assessed by the Mini-Mental state examination (MMSE), which is scored 0-30.
measure: Change in cognitive assessment scale score(MoCA)
time frame: 1 year
description: It will be assessed by the Montreal cognitive assessment (MoCA), which is scored 0-30.
measure: the prevalence of gait disorders
time frame: baseline
description: the prevalence of gait disorders, according to the intelligent assessment
measure: the prevalence of cognitive disorder
time frame: baseline
description: the prevalence of cognitive disorder, according to the MMSE
measure: the incidence of vascular events
time frame: 1 year
description: the incidence of vascular events, including Cardiovascular and cerebrovascular events
measure: the incidence of fall incidence
time frame: 1 year
description: the incidence of fall incidence
arm group label: positive
description: Subjects have gait disorder according to intelligent gait assessment at baseline.
arm group label: negative
description: Subjects don't have gait disorder according to intelligent gait assessment at baseline.
intervention type: Other
intervention name: there is no intervention
description: There is no intervention
arm group label: negative
arm group label: positive
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 60 Years
maximum age: 85 Years
healthy volunteers: No
last name: Jing Ding, MD
role: Study Director
affiliation: Shanghai Zhongshan Hospital
last name: Beini Fei, MB
phone: +86 13701699684
email: fbeini@sina.com
citation: Poels MM, Steyerberg EW, Wieberdink RG, Hofman A, Koudstaal PJ, Ikram MA, Breteler MM. Assessment of cerebral small vessel disease predicts individual stroke risk. J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1174-9. doi: 10.1136/jnnp-2012-302381. Epub 2012 Aug 23.
PMID: 22917672
citation: Kim BJ, Lee SH. Prognostic Impact of Cerebral Small Vessel Disease on Stroke Outcome. J Stroke. 2015 May;17(2):101-10. doi: 10.5853/jos.2015.17.2.101. Epub 2015 May 29.
PMID: 26060797
citation: Sachdev PS, Wen W, Christensen H, Jorm AF. White matter hyperintensities are related to physical disability and poor motor function. J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):362-7. doi: 10.1136/jnnp.2004.042945.
PMID: 15716527
citation: Murray ME, Senjem ML, Petersen RC, Hollman JH, Preboske GM, Weigand SD, Knopman DS, Ferman TJ, Dickson DW, Jack CR Jr. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol. 2010 Nov;67(11):1379-85. doi: 10.1001/archneurol.2010.280.
PMID: 21060015
citation: Wakefield DB, Moscufo N, Guttmann CR, Kuchel GA, Kaplan RF, Pearlson G, Wolfson L. White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults. J Am Geriatr Soc. 2010 Feb;58(2):275-81. doi: 10.1111/j.1532-5415.2009.02699.x. Epub 2010 Jan 26.
PMID: 20374403
citation: Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010 Jul 26;341:c3666. doi: 10.1136/bmj.c3666.
PMID: 20660506
citation: Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012 Dec;69(12):1621-7. doi: 10.1001/archneurol.2012.1527.
PMID: 22945686
citation: Maillard P, Carmichael O, Fletcher E, Reed B, Mungas D, DeCarli C. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology. 2012 Jul 31;79(5):442-8. doi: 10.1212/WNL.0b013e3182617136. Epub 2012 Jul 18.
PMID: 22815562
citation: Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Greenberg SM, Higashida RT, Kasner SE, Seshadri S; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Feb;48(2):e44-e71. doi: 10.1161/STR.0000000000000116. Epub 2016 Dec 15.
PMID: 27980126
citation: Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54. doi: 10.1016/s0140-6736(13)61953-4. Erratum In: Lancet. 2014 Jan 18;383(9913):218.
PMID: 24449944
citation: Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16(3):280-5. doi: 10.1159/000071128.
PMID: 12865617
citation: Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003 May;34(5):1126-9. doi: 10.1161/01.STR.0000068408.82115.D2. Epub 2003 Apr 10.
PMID: 12690219
citation: Kim YJ, Kwon HK, Lee JM, Cho H, Kim HJ, Park HK, Jung NY, San Lee J, Lee J, Jang YK, Kim ST, Lee KH, Choe YS, Kim YJ, Na DL, Seo SW. Gray and white matter changes linking cerebral small vessel disease to gait disturbances. Neurology. 2016 Mar 29;86(13):1199-207. doi: 10.1212/WNL.0000000000002516. Epub 2016 Mar 2.
PMID: 26935893
citation: de Laat KF, van Norden AG, Gons RA, van Oudheusden LJ, van Uden IW, Bloem BR, Zwiers MP, de Leeuw FE. Gait in elderly with cerebral small vessel disease. Stroke. 2010 Aug;41(8):1652-8. doi: 10.1161/STROKEAHA.110.583229. Epub 2010 Jun 24.
PMID: 20576951
citation: Montero-Odasso MM, Sarquis-Adamson Y, Speechley M, Borrie MJ, Hachinski VC, Wells J, Riccio PM, Schapira M, Sejdic E, Camicioli RM, Bartha R, McIlroy WE, Muir-Hunter S. Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment: Results From the Gait and Brain Study. JAMA Neurol. 2017 Jul 1;74(7):857-865. doi: 10.1001/jamaneurol.2017.0643. Erratum In: JAMA Neurol. 2017 Nov 1;74(11):1381.
PMID: 28505243
citation: Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 Aug;12(8):822-38. doi: 10.1016/S1474-4422(13)70124-8.
PMID: 23867200
citation: Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007 Jul;6(7):611-9. doi: 10.1016/S1474-4422(07)70170-9.
PMID: 17582361
citation: Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med. 2002 Nov 28;347(22):1761-8. doi: 10.1056/NEJMoa020441.
PMID: 12456852
citation: Dumurgier J, Artaud F, Touraine C, Rouaud O, Tavernier B, Dufouil C, Singh-Manoux A, Tzourio C, Elbaz A. Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. J Gerontol A Biol Sci Med Sci. 2017 May 1;72(5):655-661. doi: 10.1093/gerona/glw110.
PMID: 27302701
responsible party type: Sponsor
mesh term: Cerebrovascular Disorders
sharing ipd: No